News

EATG did research into the use of PROMs for the development of new HIV medicines. Led by the community, the work comprised of a literature review, a survey with people living with HIV taking treatment and stakeholder interviews. The purpose of the work is to describe the current use of PROMs in HIV research and development as well as to inform an advocacy agenda to guide the use and development of PROMs, highlighting the role of communities living with or affected by HIV. It provides a concrete set of recommendations for people living with HIV, pharmaceutical companies, researchers/clinicians and regulatory bodies/HTAs.
Read the full report

Dear EACS members, dear friends,

It is with deep sadness that we learned of the death of Charles Boucher. An acclaimed researcher and professor, Dr Boucher was a profoundly important international leader in the fight against HIV and AIDS. He was professor in Virology at the Erasmus Medical Center in Rotterdam and scientific director at Virology Education, Utrecht, Netherlands. Among many important research cooperations and initiatives he was a pivotal driver of SPREAD (Strategy to Control SPREAD of HIV Drug Resistance), an HIV-drug resistance surveillance program that studied the transmission of drug resistant HIV and a board member of the European Society for Translational Antiviral Research (ESAR). While celebrating the tremendous scientific and academic accomplishments that mark the prolific career of Dr Boucher, we mourn not only the loss of a great humanitarian and inspired teacher but also of what he might have brought to the fight against HIV and AIDS around the world in the years ahead. He was paramount in delivering medical education in the HIV space all over the world with an amazing variety of spot-on topics and a very active supporter of young talent. Above all he was a very gentle, humorous and fun person to be with. He will be missed terribly. 

Sanjay Bhagani, President

Jürgen Rockstroh, Immediate Past President

17-20 May 2021

The next International Symposium on HIV and Emerging Infectious Diseases (ISHEID) will exceptionnally be virtual and is scheduled from 17 to 20 May, 2021.
The understanding of HIV and HCV infections continues to grow rapidly, especially regarding our ability to develop novel prevention and therapeutic strategies that will lead to the reduction of new infections. The burden of non communicable diseases in HIV infected subjects implicates a multidisciplinary approach of the infection and the need of close interactions with specialists from other disciplines.
ISHEID 2021 will dedicate a privileged place to state-of-the-art presentations, as well as to debates among experienced and younger investigators regarding new data and their implications. This event will have invited lectures by European and International leaders, as well as oral abstracts and poster presentations.
It will be unique in its approach, as it will engage basic scientists and clinicians from the HIV, HCV and emerging infectious diseases fields.

Read more

Guidance on COVID-19 for people living with HIV (PLWH)

Read more

С ним можно ознакомиться здесь 

The journal of Virus Eradication published an article on the WAVE’s survey on PrEP in women : "Achievements and gaps to provide pre-exposure prophylaxis (PrEP) for women across the European Region - Results from a European survey study"

Read the article 

The new Governing Board has been elected among the EACS members of their respective regions; their mandates started on 1 January 2021.  

Read more

Dear EACS members, dear friends,

2020 was an ‘annus horribilis’ for all of us; many have lost family members and dear friends to the COVID-19 pandemic; our working lives and personal lives have changed immeasurably.
But 2021 is the dawn of new era. The Sars-Cov2 vaccines are on the horizon; there is hope that this year we can return to ‘normality’ whatever that will mean for a world that has changed so much.

Read more

The abstract submission for the HepHIV 2021 Lisbon & Virtual Conference is now open with abstract deadline on 7 February, 2021. 

Abstract submissions are invited for the HepHIV 2021 Lisbon & Virtual Conference. The call for abstracts for HepHIV 2021 closes on 7 February 2021 and abstract decisions will be communicated to authors early April 2021.
Submit an abstract (Chrome is the preferred browser)

More info

If you are interested in receiving information on the HepHIV 2021 Hybrid Conference, please sign-up here http://eepurl.com/gGpMt1